Mindset

Shmoop Announces New Capabilities for Districts in its Heartbeat Product

Retrieved on: 
Monday, October 3, 2022
Graduate, Bart Simpson's Guide to Life, Student, Certification, Chalk It Up, Assistant, Pasadena Unified School District, ASU, SEL, LEHI, Learnosity, Mindset, School, Education, Goal, Digital Promise, Blog, Medicine, Heartbeat, Portrait, Collection

LEHI, Utah, Oct. 3, 2022 /PRNewswire-PRWeb/ -- Shmoop, the award-winning digital education solutions provider, has announced the release of groundbreaking new features being added to its tool, Heartbeat.

Key Points: 
  • Shmoop's award-winning tool, Heartbeat, gets new features becoming the first edtech tool to help districts measure large initiatives.
  • LEHI, Utah, Oct. 3, 2022 /PRNewswire-PRWeb/ -- Shmoop , the award-winning digital education solutions provider, has announced the release of groundbreaking new features being added to its tool, Heartbeat.
  • "The addition of "Collections" in Heartbeat allows a district to better define the components of their district-wide initiatives like "Portrait of a Graduate" or "Guide-for-Life."
  • Shmoop's research-based classroom technology, Heartbeat, focuses on a student's emotional health, cognitive position, and background to improve their ability to achieve academically ( http://www.shmoop.com ).

Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

Retrieved on: 
Tuesday, September 27, 2022
Alternative Medicine, Mental Health, Health, General Health, Pharmaceutical, Biotechnology, Therapy, Time, Safety, Engineering, Psychedelic drug, EDGAR, NYSE, Food, Disease, FSE, U.S. Securities and Exchange Commission, Psilocybin, Company, Inc., View, News, Growth, Catalog, Forward-looking statement, Patient, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NEO, CSE, Health Canada, United Kingdom, Goal, Lists of diseases, Drug development, NYSE American, Agreement, Research, MSET, Pharmaceutical industry, Mindset, Milestone (disambiguation)

Pursuant to the Agreement, Cybin has paid Mindset a one-time license fee of US $500,000 with additional milestones payable upon the successful completion of certain future milestones.

Key Points: 
  • Pursuant to the Agreement, Cybin has paid Mindset a one-time license fee of US $500,000 with additional milestones payable upon the successful completion of certain future milestones.
  • This exclusive license bolsters the breadth of Cybins IP holdings while adding a significant number of compounds to our growing library of psychedelic derivative drug development candidates, said Doug Drysdale, Cybins Chief Executive Officer.
  • We are pleased to work with Mindset who, like Cybin, has a deep-rooted understanding of psychedelic science.
  • Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

Retrieved on: 
Tuesday, September 27, 2022
Development, Trial of the century, NYSE, FSE, Otsuka Pharmaceutical, Patient, CEO, NEO, CSE, Agreement, GLOBE, Drug discovery, MSET, Pharmaceutical industry, Mindset

Under the terms of the Agreement, Cybin will license intellectual property related to preclinical compounds within Mindsets Family 1 portfolio, excluding MSP-1014, Mindsets lead psychedelic drug candidate.

Key Points: 
  • Under the terms of the Agreement, Cybin will license intellectual property related to preclinical compounds within Mindsets Family 1 portfolio, excluding MSP-1014, Mindsets lead psychedelic drug candidate.
  • Both our companies share the same ultimate goal of discovering and developing superior new psychedelic treatments to better meet the needs of patients, said James Lanthier, CEO of Mindset Pharma.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

New Research: Half of Americans Have Reset Priorities Due to Pandemic Effects

Retrieved on: 
Wednesday, September 21, 2022
Adult, Mindset, Health, Research, Population, Private sector, Review, Friends, Policy, Motivation, Risk management, Pharmaceutical industry, Census

WASHINGTON, Sept. 21, 2022 /PRNewswire-PRWeb/ -- Half (51%) of Americans say the pandemic created the opportunity for a personal reset; the opening they needed to do something different with their lives. Those who are younger, Hispanic, or Black are most likely to say the pandemic was a reset.

Key Points: 
  • Half (51%) say the pandemic created the opportunity for a personal reset.
  • WASHINGTON, Sept. 21, 2022 /PRNewswire-PRWeb/ -- Half (51%) of Americans say the pandemic created the opportunity for a personal reset; the opening they needed to do something different with their lives.
  • Those who are younger, Hispanic, or Black are most likely to say the pandemic was a reset.
  • "The experience of the pandemic has changed personal priorities for many," said Anne Aldrich, Partner at Artemis Strategy Group.

Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Retrieved on: 
Wednesday, September 14, 2022
Cyclothymia, Safety, Development, Family, FSE, MDD, CTA, Company, Otsuka Pharmaceutical, Review, Patient, Clinical trial, CEO, CSE, CRO, Family 1, MHRA, Contract research organization, Scientific Advice Mechanism, GLOBE, Health care, Drug discovery, MSET, Pharmaceutical industry, Mindset

The MHRA has agreed with the Companys position and confirmed that, subject to CTA review, MSP-1014 will not require additional preclinical studies at this time.

Key Points: 
  • The MHRA has agreed with the Companys position and confirmed that, subject to CTA review, MSP-1014 will not require additional preclinical studies at this time.
  • The MHRA has also provided specific valuable guidance on potential clinical trial design regarding dosing, patient selection criteria, and safety endpoints.
  • Given its differentiation and improved pharmacological profile, Mindset prioritized moving MSP-1014 to first-in-human clinical studies.
  • We are thrilled to have received this favorable written guidance from the MHRA, confirming the readiness of MSP-1014 for Phase 1 first-in-human clinical development.

Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

Retrieved on: 
Wednesday, September 7, 2022
CEO, CSE, Safety, Psilocybin, MSET, USPTO, FSE, Family 1, Otsuka Pharmaceutical, GLOBE, Company, Family, IP, Drug discovery, Intellectual property, Development, Patient, Pharmaceutical industry, Mindset

MSP-1014 has demonstrated improved efficacy, with reduced potential side effects, and safety profile compared to the first-generation drug candidate, psilocybin, in preclinical studies.

Key Points: 
  • MSP-1014 has demonstrated improved efficacy, with reduced potential side effects, and safety profile compared to the first-generation drug candidate, psilocybin, in preclinical studies.
  • Mindset filed national applications in 16 different countries altogether, including the principal South East Asian markets.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

Retrieved on: 
Wednesday, August 31, 2022
ADME, FTO, CEO, CSE, Research and development, Psilocybin, Central nervous system, MSET, Tryptamine, Intellectual property, DMT, FSE, Absorption, Otsuka Pharmaceutical, GLOBE, Glycoside hydrolase family 6, IP, Drug discovery, Metabolism, CNS, Development, Patient, Pharmaceutical industry, Mindset

While much of the industry focus has been on classic psychedelic drugs, Mindset has purposefully expanded its discovery efforts beyond the tryptamine drug class (i.e.

Key Points: 
  • While much of the industry focus has been on classic psychedelic drugs, Mindset has purposefully expanded its discovery efforts beyond the tryptamine drug class (i.e.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds.

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Retrieved on: 
Tuesday, August 30, 2022
CEO, CSE, MSET, FSE, CSO, Otsuka Pharmaceutical, GLOBE, Conference, Lotte New York Palace Hotel, Drug discovery, Development, Pharmaceutical industry, Mindset

Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Patrick Trucchio, H.C. Wainwright Research Analyst, on Tuesday, September 13th at 9:30 a.m.

Key Points: 
  • Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Patrick Trucchio, H.C. Wainwright Research Analyst, on Tuesday, September 13th at 9:30 a.m.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds.

Solution Tree, Marzano Resources Titles Win Publishing Awards

Retrieved on: 
Friday, August 19, 2022
Classroom, GLOBE, Mindset, Learning, IBPA, NBA Rookie of the Year Award, IPPY, Silver, Solution Tree, Workforce, Gold, Marzano, Medicine

Bloomington, Ind., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Educational professional development books published by Solution Tree and Marzano Resources are once again at the top of three major book award lists for 2021 and 2022.

Key Points: 
  • Bloomington, Ind., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Educational professional development books published by Solution Tree and Marzano Resources are once again at the top of three major book award lists for 2021 and 2022.
  • The Metacognitive Student , Finding Your Blind Spots , Mindsets & Skill Sets for Learning , and The School Wellness Wheel received top honors in the Education I (Workbook/Resources) category at the 2022 Independent Publisher (IPPY) Book Awards.
  • Conducted annually, the IPPY Awards honor the years best independently published titles from around the world.
  • Two more titles The Metacognitive Student and Capturing the Classroom received a gold medal and an honorable mention, respectively, in the 2021 Foreword INDIES Book of the Year Awards .

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

Retrieved on: 
Tuesday, August 9, 2022
CFOS, GLOBE, Cmax, BDNF, Addiction, Brain, Patent, Board, Center, Research, Ōtsuka, Pharmacology, Patient, AUC, Board of directors, Overalls, Lists of diseases, FSE, Industry, CNS, Technology, Psychiatry, United States Patent and Trademark Office, DMT, Partnership, CAMH, Safety, CSO, Otsuka Pharmaceutical, Contract research organization, CSE, Family 1, Family II, Drug discovery, Growth, Glycoside hydrolase family 4, NCE, Drug development, Mental health, Centre for Addiction and Mental Health, Health care, Invention, MSET, RATS, IP, Psilocybin, Review, Drug design, Therapy, Central nervous system, Treatment, USPTO, Pharmaceutical industry, Fine chemical, Development, Mindset

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • The development of this proprietary formulation technology is yet another excellent example of the dedication and scientific innovation engine from the Mindset team.
  • At Mindset, we also understand the immense value of strategic scientific and business partnerships with industry leading experts.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.